Paclitaxel Pharmacokinetics And Response To Chemotherapy In Patients With Advanced Cancer Treated With A Weekly Regimen
This studied followed others in observing that paclitaxel pharmacokinetics (time above a threshold concentration Tc>0.05) was associated with pharmacodynamic effect. In patients with heterogeneous tumor types (n=29) these investigators found paclitaxel exposure influenced both toxicity and outcome. In addition, patients with partial responses or stable disease had higher paclitaxel exposure than patients with progressive disease (p=0.039). In a separate publication from the same study, patients who developed peripheral neuropathy also had significantly higher paclitaxel levels (Tc>0.05, p=0.22).